Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CpG DNA is a synthetic oligonucleotide containing unmethylated cytosine-guanine (CpG) motifs that mimic bacterial and viral DNA. It acts as a potent agonist of Toll-like receptor 9 (TLR9), an endosomal receptor expressed primarily in plasmacytoid dendritic cells and B cells. Activation of TLR9 induces an innate immune response characterized by the secretion of pro-inflammatory cytokines (such as IFN-alpha, IL-12, and TNF-alpha) and the maturation of antigen-presenting cells, which subsequently promotes a Th1-biased adaptive immune response. Dalian University has evaluated CpG DNA in clinical trials for hepatocellular carcinoma, specifically as an adjuvant therapy combined with transcatheter arterial chemoembolization (TACE) to stimulate anti-tumor immunity following local tumor destruction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CpG DNA.